Final results of a randomized phase II study of OGX-011 (OGX) in combination with docetaxel (DOC)/prednisone versus docetaxel/prednisone in patients with metastatic castration resistant prostate cancer (CRPC)

被引：0
|
作者：
Chi, K. N. [1 ]
Hotte, S. J. [2 ]
Yu, E. [3 ]
Tu, D.
Eigl, B. [5 ]
Tannock, I. [6 ]
Saad, F. [7 ]
North, S. [8 ]
Powers, J. [4 ]
Eisenhauer, E. [4 ]
机构：
[1] BC Canc Agcy, Vancouver, BC 98195, Canada
[2] Juravinski Canc Ctr, Hamilton, ON, Canada
[3] Univ Washington, Seattle, WA USA
[4] NCIC Clin Trials Grp, IND Program, Kingston, ON M4X 1K9, Canada
[5] Tom Baker Canc Clin, Calgary, AB, Canada
[6] Princess Margaret Hosp, Toronto, ON T6G 1Z2, Canada
[7] Univ Montreal, Ctr Hosp, Montreal, PQ, Canada
[8] Cross Canc Inst, Edmonton, AB, Canada
来源：
EJC SUPPLEMENTS | 2009年 / 7卷 / 02期
关键词：
D O I：
10.1016/S1359-6349(09)71382-5
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：407 / 407
页数：1
相关论文
共 50 条
  • [1] Mature results of a randomized phase II study of OGX-011 in combination with docetaxel/prednisone versus docetaxel/prednisone in patients with metastatic castration-resistant prostate cancer
    Chi, K. N.
    Hotte, S. J.
    Yu, E.
    Tu, D.
    Eigl, B.
    Tannock, I.
    Saad, F.
    North, S.
    Powers, J.
    Eisenhauer, E.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [2] Randomized Phase II Study of Docetaxel and Prednisone With or Without OGX-011 in Patients With Metastatic Castration-Resistant Prostate Cancer
    Chi, Kim N.
    Hotte, Sebastien J.
    Yu, Evan Y.
    Tu, Dongsheng
    Eigl, Bernhard J.
    Tannock, Ian
    Saad, Fred
    North, Scott
    Powers, Jean
    Gleave, Martin E.
    Eisenhauer, Elizabeth A.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (27) : 4247 - 4254
  • [3] A randomized phase II study of OGX-011 in combination with docetaxel and prednisone or docetaxel and prednisone alone in patients with metastatic hormone refractory prostate cancer (HRPC)
    Chi, K. N.
    Hotte, S. J.
    Yu, E.
    Eigl, B. J.
    Tannock, I.
    Saad, F.
    North, S.
    Powers, J.
    Eisenhauer, E.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [4] Phase II Trial of OGX-011 in Combination with Docetaxel in Metastatic Breast Cancer
    Chia, Stephen
    Dent, Susan
    Ellard, Susan
    Ellis, Peter M.
    Vandenberg, Ted
    Gelmon, Karen
    Powers, Jean
    Walsh, Wendy
    Seymour, Lesley
    Eisenhauer, Elizabeth A.
    [J]. CLINICAL CANCER RESEARCH, 2009, 15 (02) : 708 - 713
  • [5] A randomized phase II study of OGX-427 plus prednisone (P) versus P alone in patients (pts) with metastatic castration resistant prostate cancer (CRPC)
    Chi, Kim N.
    Hotte, Sebastien J.
    Ellard, Susan
    Gingerich, Joel Roger
    Joshua, Anthony Michael
    Yu, Evan Y.
    Gleave, Martin Edwin
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [6] Custirsen (OGX-011) combined with cabazitaxel and prednisone versus cabazitaxel and prednisone alone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel (AFFINITY): a randomised, open-label, international, phase 3 trial
    Beer, Tomasz M.
    Hotte, Sebastien J.
    Saad, Fred
    Alekseev, Boris
    Matveev, Vsevolod
    Flechon, Aude
    Gravis, Gwenaelle
    Joly, Florence
    Chi, Kim N.
    Malik, Zafar
    Blumenstein, Brent
    Stewart, Patricia S.
    Jacobs, Cindy A.
    Fizazi, Karim
    [J]. LANCET ONCOLOGY, 2017, 18 (11): : 1532 - 1542
  • [7] A randomized phase II study of OGX-427 plus prednisone versus prednisone alone in patients with chemotherapy-naive metastatic castration-resistant prostate cancer.
    Chi, Kim N.
    Hotte, Sebastien J.
    Ellard, Susan
    Gingerich, Joel Roger
    Joshua, Anthony Michael
    Kollmannsberger, Christian K.
    Yu, Evan Y.
    Gleave, Martin Edwin
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (05)
  • [8] A RANDOMIZED PHASE II STUDY OF OGX-427 PLUS PREDNISONE (P) VS. P ALONE IN PATIENTS (PTS) WITH METASTATIC CASTRATION RESISTANT PROSTATE CANCER (CRPC)
    Chi, K.
    Yu, E. Y.
    Ellard, S.
    Hotte, S. J.
    Gingerich, J. R.
    Joshua, A. M.
    Gleave, M. E.
    [J]. ANNALS OF ONCOLOGY, 2012, 23 : 297 - 297
  • [9] A phase I study of OGX-011, a 2′-methoxyethyl phosphorothioate antisense to clusterin, in combination with docetaxel in patients with advanced cancer
    Chi, Kim N.
    Siu, Lillian L.
    Hirte, Hal
    Hotte, Sebastien J.
    Knox, Jennifer
    Kollmansberger, Christian
    Gleave, Martin
    Guns, Emma
    Powers, Jean
    Walsh, Wendy
    Tu, Dongsheng
    Eisenhauer, Elizabeth
    [J]. CLINICAL CANCER RESEARCH, 2008, 14 (03) : 833 - 839
  • [10] CUOG PHASE II RANDOMIZED STUDY OF CUSTIRSEN (OGX-011) COMBINATION THERAPY IN PATIENTS WITH CASTRATE RESISTANT PROSTATE CANCER (CRPC) WHO RELAPSED ON OR WITHIN SIX MONTHS OF 1ST-LINE DOCETAXEL THERAPY
    Saad, Fred
    Hotte, Sebastien
    North, Scott
    Eigl, Bernard
    Chi, Kim
    Czaykowski, Piotr
    Pollak, Michael
    Wood, Lori
    Winquist, Eric
    [J]. JOURNAL OF UROLOGY, 2009, 181 (04): : 229 - 230
12345